Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02753790 · ClinicalTrials.gov registry record · NA

Whole Brain Radiation Using IMRT for Patients With Brain Metastases

A NA study, sponsored by New Mexico Cancer Research Alliance.

Completed
Registry status
NA
Development phase
29
Enrollment target

NCT02753790: Completed NA study, sponsored by New Mexico Cancer Research Alliance.

NCT02753790 is a NA study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 29 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02753790, a NA study, has completed, sponsored by New Mexico Cancer Research Alliance.

COMPLETED
Registry status
NA
Development phase
29 participants
Enrollment target

Study Summary

Some cancers can spread, or metastasize, to the brain. When they do, treatment often involves surgery and/or radiation. Optimal treatment of brain metastases would maximize disease control and minimize toxicity (or side effects), and improve the quality of life of patients. A common type of radiation used for brain metastases is called whole brain radiation, which treats not just the cancer that can be seen on scans (i.e., gross disease), but the smaller sites of cancer that may not be visible (i.e. subclinical disease). Fractionation is used to describe repetitive treatments in which small doses (fractions) of a total planned dose are given at separate clinic visits. The most common dosing regimen is 30 Gray (Gy), using 3 Gy per fraction over 10 fractions. Previous studies have suggested that using intensity modulated radiation therapy (IMRT) may be a safer way to deliver higher doses to gross disease and lower doses to the rest of the brain that may contain subclinical disease. This approach may spare the rest of the brain from radiation complications and side effects. The goal of this study is to determine whether using IMRT to treat brain metastases is more effective than current standard whole brain radiation in controlling gross disease and whether patient quality of life and hair loss is improved compared to previous studies using whole brain radiation.

Primary Outcome

Overall response rate (ORR) is the sum of the percentage of patients who achieve a complete response (CR) or partial response (PR). CR is defined as a total radiographic disappearance of all lesions with stabilization of the neurological examination after glucocorticoids have been stopped. PR is defined as a greater than 50% decrease in volume of all lesions as measured radiographically with improvement or stabilization of the neurological examination with stable glucocorticoid dose.

Interventions

  • RADIATION Intensity Modulated Radiotherapy

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2016-03-09
Est. Completion 2022-04-10
Phase NA

What the finished NCT02753790 record still lists

NCT02753790 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Intensity Modulated Radiotherapy is the first listed.

NCT02753790 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02753790 about?

NCT02753790 is a clinical study titled "Whole Brain Radiation Using IMRT for Patients With Brain Metastases". Some cancers can spread, or metastasize, to the brain. When they do, treatment often involves surgery and/or radiation. Optimal treatment of brain metastases would maximize disease control and minimize toxicity (or side effects), and improve the quality of life of patients. A common type of radiatio...

What is the current status of trial NCT02753790?

This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2016-03-09. Estimated completion is 2022-04-10.

What interventions are being tested in trial NCT02753790?

The interventions under investigation include: Intensity Modulated Radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT02753790?

This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02753790's enrollment target sits among peer trials

29 1702nd of 2000 higher than 297 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02753790, the US trial registry maintained by the National Library of Medicine. NCT02753790 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.